Laboratory of Molecular Microbiology, Department of Microbiology and Parasitology, University of The Andes, Mérida, Venezuela
Copyright ©2018, Korea Centers for Disease Control and Prevention
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflicts of Interest
No potential conflict of interest relevant to this article was reported.
Characteristics | Detection of ESBL n (%) |
Multivariate OR (95% CI) |
p | |
---|---|---|---|---|
Positive 27 (34.6) |
Negative 51 (65.4) | |||
Gender | ||||
| ||||
Male | 14 (51.9) | 28 (54.9) | 1 | |
| ||||
Female | 13 (48.1) | 23 (45.1) | 1.130 (0.444–2.880) | 0.9853 |
| ||||
Age | ||||
| ||||
1 – ≤ 2.5 | 7 (25.9) | 37 (72.6) | 1 | |
| ||||
≥ 2.5 – ≤5 | 20 (74.1) | 14 (27.4) | 7.551 (2.621–21.754) | 0.0002 |
| ||||
Variety of food in weekly diet | ||||
| ||||
Still breast-feeding | 6 (22.2) | 31 (60.8) | ||
| ||||
Two or more different type of animal-origin food | 21 (77.8) | 20 (39.2) | 5.425 (1.865–15.778) | 0.0026 |
| ||||
Hygiene habit (hand washing) | ||||
| ||||
Water | 5 (18.5) | 22 (43.1) | 1 | |
| ||||
Water and soap | 22 (81.5) | 29 (56.9) | 3.338 (1.091–10.213) | 0.0543 |
| ||||
Household crowding | ||||
| ||||
No | 9 (33.3) | 23 (45.1) | ||
| ||||
Yes | 18 (66.7) | 28 (54.9) | 0.609 (0.230–1.609) | 0.4455 |
| ||||
Hospital admission in the last year | ||||
| ||||
No | 22 (81.5) | 46 (90.2) | 1 | |
| ||||
Yes | 5 (18.5) | 5 (9.8) | 2.091 (0.548–7.985) | 0.4597 |
| ||||
Antibiotic consumption within the last 3 months | ||||
| ||||
No | 22 (81.5) | 50 (98.0) | 1 | |
| ||||
Yes | 5 (18.5) | 1 (2.0) | 11.364 (1.252–103.11) | 0.0304 |
Antibiotic | MIC Range (μg/ml) | Antimicrobial susceptibility n (%) | ||
---|---|---|---|---|
Susceptible | Intermediate | Resistant | ||
Ampicillin/sulbactam | ≤8/4 – ≥32/16 | 77 (98.7) | - | 1 (1.3) |
Piperacillin/tazobactam | ≤16/4 – ≥128/4 | 78 (100) | - | 0 (0.0) |
Cefoxitin | ≤8 – ≥32 | 73 (93.6) | - | 5 (6.4) |
Ceftazidime | ≤4 – ≥16 | 52 (66.7) | - | 26 (33.3) |
Cefotaxime | ≤1 – ≥4 | 51 (65.4) | - | 27 (34.6) |
Cefepime | ≤2 – ≥16 | 60 (72.9) | - | 18 (23.1) |
Aztreonam | ≤4 – ≥16 | 52 (66.7) | - | 26 (33.3) |
Ertapenem | ≤0,5 – ≥32 | 78 (100) | - | 0 (0.0) |
Imipenem | ≤1 – ≥4 | 78 (100) | - | 0 (0.0) |
Meropenem | ≤1 – ≥4 | 78 (100) | - | 0 (0.0) |
Amikacin | ≤16 – ≥64 | 71 (91.0) | 2 (2.6) | 5 (6.4) |
Gentamicin | ≤4 – ≥16 | 72 (92.3) | - | 6 (7.7) |
Nalidixic acid | ≤16 – ≥32 | 72 (92.3) | 2 (2.6) | 4 (5.1) |
Ciprofloxacin | ≤0,06– ≥1 | 71 (91.0) | 3 (3.8) | 4 (5.1) |
Tigecycline | ≤0,1 – ≥16 | 78 (100) | - | 0 (0.0) |
Colistin | ≤0,5 – ≥64 | 78 (100) | - | 0 (0.0) |
Susceptibility profile of Escherichia coli n=78 | |||
---|---|---|---|
ESBL n= 27 (34.6%) |
n° (%) | non-ESBL n= 51 (65.4%) |
n° (%) |
ESBL + | 17 (63.0) | Susceptible | 44 (86.3) |
ESBL + GEMR | 2 (7.4) | AMKI | 2 (3.9) |
ESBL + NALR | 2 (7.4) | CIPI | 2 (3.9) |
ESBL + AMKR | 1 (3.7) | NALI | 1(2.0) |
ESBL + NALR + CIPR | 1 (3.7) | NALR | 1(2.0) |
ESBL + AMKR + GEMR | 1 (3.7) | NALI + CIPI | 1(2.0) |
ESBL + AMKR + GEMR + CIPR | 3 (11.1) | ||
Total | 27 (100) | Total | 51 (100) |
Gene blaESBLs |
Phylogenetic group n = 27 |
Total | |||
---|---|---|---|---|---|
A | B1 | B2 | D | n (%) | |
blaCTX-M-15 | 9 | 2 | 6 | 2 | 19 (70.4) |
blaCTX-M-15 + blaTEM-1 | 1 | 1 | 1 | 0 | 3 (11.1) |
blaCTX-M-15 + blaTEM-5 | 2 | 0 | 0 | 0 | 2 (7.4) |
blaCTX-M-15 + blaSHV-5 | 1 | 0 | 1 | 0 | 2 (7.4) |
blaCTX-M-15 + blaSHV-12 | 1 | 0 | 0 | 0 | 1 (3.7) |
Total (%) | 14 (51.9) | 3 (11.1) | 8(29.6) | 2 (7.4) | 27 (100) |
MIC: minimal inhibitory concentration.
AMK: amikacin; CIP: ciprofloxacin; R: resistant; I: intermediate susceptibility; ESBL: extended-spectrum-β-lactamase; GEM: gentamicin; NAL: nalidixic acid;